home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2822.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
47 lines
Document 2822
DOCN M94A2822
TI CD4 cell count of HIV1 asymptomatic patients remains stable under
cyclosporin A.
DT 9412
AU Levy R; Tourani JM; Jais JP; Even P; Andrieu JM; Hopital Laennec
Universite Paris V, France.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):217 (abstract no. PB0298). Unique
Identifier : AIDSLINE ICA10/94369753
AB OBJECTIVE: We conducted a pilot study to test whether CSA could
slow-down the CD4 cell count decline in asymptomatic HIV-1 infected
patients (pts) by decreasing virus replication associated with CD4 cell
activation and/or suppressing virus induced immune/auto-immune
phenomena). METHODS: From Sept 1985 to Nov 1987 all HIV-1 seropositive
pts followed at our institution having signed informed consent with CDC
stage II/III and CD4 cells between 300-600/microliters were given CSA
twice daily at 3.75 mg/kg. Dose was adapted to reach plasma levels of
100 to 300 ng/ml. Biological and physical examinations were regularly
done. RESULTS: 27 pts were enrolled in the study. No pt was withdrawn
from analysis. There were 22 male, 5 females. (homosex: 19, heterosex:
4, IVDA: 4), mean age: 37 years (min: 23--max: 68). There were 11 pts
CDC II, 16 CDCIII. Initial median CD4 cell count (cells/microliters) was
:523 (min 302--max 587). Median duration of CSA treatment was 11 months
(min: 2, max 64). Median follow-up (FU) after CSA cessation was 45
months (min: 2, max: 85), Toxicities were: paresthesia grade II: 5, III:
1, renal grade II: 1, III: 1, IV: 12, anemia or thrombopenia grade II:
1, III: 2, IV: 1, hepatic grade II: 2, Grade III: 2. Reasons for CSA
cessation were: CD4 decrease: 7; renal toxicity: 7, pts wish: 5,
thrombopenia: 3, hepatitis 2, paresthesia: 1, hemolytic anemia: 1,
hypertension: 1. Under CSA no pt evolved towards AIDS. Results of
repeated analysis measures of variances* (BMDP5V program) was done:
TABULAR DATA, SEE ABSTRACT VOLUME. CONCLUSION: During CSA treatment
(median duration 11 months) the CD4 cell count remained stable and no
clinical AIDS occurred. During the FU period following CSA cessation
(median 45 months) the CD4 cell count decreased at its usual rate.
DE Autoimmunity/DRUG EFFECTS Bone Marrow Diseases/CHEMICALLY INDUCED
Cyclosporine/ADVERSE EFFECTS/*PHARMACOLOGY/THERAPEUTIC USE Drug
Evaluation Human HIV Core Protein p24/BLOOD HIV
Infections/BLOOD/*DRUG THERAPY/IMMUNOLOGY HIV-1/DRUG EFFECTS/PHYSIOLOGY
Kidney Diseases/CHEMICALLY INDUCED Leukocyte Count/*DRUG EFFECTS
Paresthesia/CHEMICALLY INDUCED Pilot Projects Treatment Outcome *T4
Lymphocytes Virus Replication/DRUG EFFECTS MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).